RMD1307

RMD1307 is an investigational gene therapy being developed by Remedium Bio for the treatment of sarcopenia, a condition characterized by age-related muscle loss and decline in physical function. The therapy utilizes the company's proprietary 'Prometheus' platform to deliver the follistatin (FST) gene, which encodes a protein that serves as a potent inhibitor of myostatin (GDF-8) and other members of the transforming growth factor-beta (TGF-β) superfamily that negatively regulate muscle mass. By overexpressing follistatin, RMD1307 aims to promote muscle hypertrophy, increase strength, and restore mobility. The program is designed for delivery via either adeno-associated virus (AAV) vectors or lipid nanoparticles (LNPs). As of 2024, RMD1307 is in the IND-enabling stage of development.